Thomas Yau Selected Research

Chemical and Drug Induced Liver Injury

2/2024	Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.
1/2022	Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas Yau Research Topics

Disease

65	Hepatocellular Carcinoma (Hepatoma) 04/2024 - 01/2007
34	Neoplasms (Cancer) 02/2024 - 01/2007
8	Disease Progression 06/2023 - 01/2006
6	Liver Neoplasms (Liver Cancer) 12/2023 - 11/2008
6	Colorectal Neoplasms (Colorectal Cancer) 11/2023 - 04/2009
6	Breast Neoplasms (Breast Cancer) 09/2022 - 01/2006
6	Neoplasm Metastasis (Metastasis) 01/2019 - 11/2008
5	Hepatitis B 02/2023 - 01/2009
4	Hypertension (High Blood Pressure) 02/2024 - 07/2021
3	COVID-19 01/2024 - 01/2020
3	Infections 12/2022 - 06/2017
3	Fibrosis (Cirrhosis) 01/2021 - 11/2012
2	Vomiting 04/2024 - 12/2019
2	Nausea 04/2024 - 12/2019
2	Asthenia 04/2024 - 02/2024
2	Multiple Organ Failure (MODS) 02/2024 - 01/2022
2	Tumor Lysis Syndrome 02/2024 - 01/2022
2	Varicose Veins (Varicose Vein) 02/2024 - 01/2022
2	Hepatic Encephalopathy 02/2024 - 01/2022
2	Chemical and Drug Induced Liver Injury 02/2024 - 01/2022
2	Liver Diseases (Liver Disease) 12/2022 - 09/2022
2	Inflammation (Inflammations) 01/2022 - 12/2020
2	Hepatitis 01/2022 - 06/2017
2	Cholangiocarcinoma 01/2022 - 04/2014
2	Diarrhea 01/2020 - 12/2019
2	Thrombocytopenia (Thrombopenia) 01/2019 - 12/2013
2	Colonic Neoplasms (Colon Cancer) 11/2013 - 11/2012
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 03/2013 - 03/2010
2	Stomach Neoplasms (Stomach Cancer) 01/2013 - 01/2012
2	Carcinogenesis 01/2012 - 01/2009
2	Hemangiosarcoma (Angiosarcoma) 06/2011 - 04/2008
2	Thrombosis (Thrombus) 01/2009 - 11/2008
1	Fever (Fevers) 04/2024
1	Exanthema (Rash) 04/2024
1	Pruritus (Itching) 04/2024
1	Microsatellite Instability 02/2024
1	Melanoma (Melanoma, Malignant) 02/2024
1	Sepsis (Septicemia) 02/2024
1	Aspiration Pneumonia 01/2024
1	Renal Cell Carcinoma (Grawitz Tumor) 11/2023
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2023
1	Malnutrition (Nutritional Deficiencies) 10/2023
1	Diabetes Mellitus 10/2023

Drug/Important Bio-Agent (IBA)

34	Sorafenib (BAY 43-9006)FDA Link 02/2024 - 01/2009
10	NivolumabIBA 01/2023 - 06/2017
9	cabozantinibIBA 02/2024 - 01/2020
9	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2012
8	pembrolizumabIBA 09/2023 - 01/2020
7	Bevacizumab (Avastin)FDA Link 02/2023 - 01/2009
6	atezolizumabIBA 02/2024 - 07/2020
6	Immune Checkpoint InhibitorsIBA 01/2023 - 06/2017
5	IpilimumabIBA 01/2023 - 11/2020
5	Trastuzumab (Herceptin)FDA Link 09/2022 - 01/2006
4	durvalumabIBA 12/2023 - 01/2021
4	tremelimumabIBA 12/2023 - 01/2021
4	alpha-Fetoproteins (alpha-Fetoprotein)IBA 02/2023 - 01/2011
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2023 - 01/2007
4	Tyrosine Kinase InhibitorsIBA 10/2021 - 01/2019
3	spartalizumabIBA 04/2024 - 06/2022
3	Monoclonal AntibodiesIBA 02/2024 - 01/2021
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 02/2024 - 01/2022
3	B7-H1 AntigenIBA 11/2023 - 09/2021
3	Capecitabine (Xeloda)FDA Link 01/2022 - 01/2014
3	Proteins (Proteins, Gene)FDA Link 09/2021 - 11/2008
2	capmatinibIBA 04/2024 - 01/2019
2	Alanine Transaminase (SGPT)IBA 02/2024 - 01/2022
2	VaccinesIBA 01/2023 - 12/2022
2	EpitopesIBA 12/2022 - 01/2020
2	AntibodiesIBA 12/2022 - 01/2022
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 01/2014
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2021 - 04/2008
2	neratinibIBA 10/2021 - 01/2020
2	LigandsIBA 09/2021 - 01/2021
2	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2020 - 11/2010
2	regorafenibIBA 01/2020 - 07/2017
2	Antiviral Agents (Antivirals)IBA 06/2017 - 03/2015
2	Cetuximab (Erbitux)FDA Link 01/2017 - 11/2013
2	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2016 - 04/2015
2	ArginaseIBA 04/2015 - 02/2013
2	Fluorouracil (Carac)FDA LinkGeneric 01/2014 - 04/2009
2	Leucovorin (Folinic Acid)FDA Link 01/2014 - 04/2009
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 11/2013 - 12/2012
2	NeuropeptidesIBA 03/2013 - 03/2010
1	Apoptosis Regulatory ProteinsIBA 02/2024
1	CS-1003IBA 02/2024
1	NIS-793IBA 11/2023
1	Insulin (Novolin)FDA Link 10/2023
1	Gemcitabine FDA Link 01/2023

Therapy/Procedure

36	Therapeutics 09/2023 - 11/2008
12	Drug Therapy (Chemotherapy) 01/2023 - 04/2008
3	Immunotherapy 12/2023 - 01/2021
3	Liver Transplantation 09/2022 - 02/2013
2	Neoadjuvant Therapy 12/2021 - 03/2019
2	Hepatectomy 01/2014 - 11/2013
2	Molecular Targeted Therapy 01/2013 - 09/2010
2	Adjuvant Chemotherapy 04/2010 - 04/2009
2	Radiotherapy 09/2008 - 10/2003
1	Traction 01/2024
1	Telerehabilitation 01/2024
1	Pancreatectomy 10/2023